Latest Peplin news

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

21-Dec-09

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

12-Nov-09

Letter to our CDI Holders read more

›› More News

ASX Filings

Current year | 2008 | 2007 | Archived

Current year

12-Nov-09		LEO Pharma Completes Peplin Acquisition; Peplin to Continue as an Independent Subsidiary
12-Nov-09		Letter to CDI Holders
06-Nov-09		Results of Special Meeting of Stockholders
06-Nov-09		Script for Special Meeting of Stockholders
02-Nov-09		Timetable for Peplin/LEO merger
29-Oct-09		Amended Form 10-K/A
15-Oct-09		Appendix 3B
01-Oct-09		Definitive Proxy Statement
29-Sep-09		Form 10-K
21-Sep-09		Preliminary Proxy Statement
03-Sep-09		Form 8-K - Merger with LEO Pharma
03-Sep-09		LEO Pharma to Acquire Peplin for US$287.5m
31-Aug-09		Peplin results for the financial year ended 30 June 2009
31-Aug-09		Appendix 4E
19-Aug-09		Peplin Completes Enrolment in its Final Phase 3 Clinical Trial for AK
31-Jul-09		Appendix 4C - quarterly
27-Jul-09		Appendix 3B
23-Jul-09		Final Phase 3 Clinical Trial for PEP005 Gel in AK initiated
22-Jul-09		Appendix 3B
16-Jul-09		July PEPTalk
09-Jul-09		Lapse of Options
09-Jul-09		Appendix 3B
07-Jul-09		Peplin Completes Enrolment in P3 AK Trials for PEP005 Gel
30-Jun-09		Exercise of Options
30-Jun-09		Lapse of Options
16-Jun-09		Lapse of Options
16-Jun-09		Appendix 3B
11-Jun-09		Appendix 3B
09-Jun-09		Peplin initiates Phase 3 trials for PEP005 Gel in AK
28-May-09		Peplin's Phase II AK Trial Results Published in JAAD
20-May-09		Positive Phase III AK Trial Results Details
18-May-09		Positive Results for Peplin's First Phase III AK Trial
15-May-09		Peplin Results for the Quarter Ended 31 March 2009
04-May-09		Response to ASX Query re Price
30-Apr-09		Appendix 4C - quarterly
15-Apr-09		Peplin to Participate in BayBio 2009
02-Apr-09		Lapse of Options
02-Apr-09		Appendix 3B
01-Apr-09		Form 8-K
17-Mar-09		Peplin to present at the BIO Europe Spring 2009
16-Mar-09		Peplin to present at Cowen Health Care Conference
06-Mar-09		Peplin's Positive Phase IIb AK Trial Results Details
23-Feb-09		Change of Director's Interest Notice
16-Feb-09		Appendix 3B
13-Feb-09		Peplin Results for the Quarter Ended 31 December 2008
13-Feb-09		Form 10-Q quarterly report
13-Feb-09		Half year report
12-Feb-09		Change of Director's Interest Notice
12-Feb-09		Appendix 3B
04-Feb-09		February PEPTalk
03-Feb-09		Change of Director's Interest Notice
27-Jan-09		Change of Director's Interest Notice
16-Jan-09		Change of Director's Interest Notice
15-Jan-09		Change of Director's Interest Notice
15-Jan-09		Change of Director's Interest Notice
15-Jan-09		Lapse of Options
14-Jan-09		Registration Statement
13-Jan-09		Peplin's updated corporate presentation
09-Jan-09		Positive results for Peplin's Phase IIb AK Trial
09-Jan-09		Appendix 4C - quarterly
02-Jan-09		Appendix 3B

click here to download the Adobe reader